Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
出版年份 2021 全文链接
标题
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
作者
关键词
-
出版物
Vaccines
Volume 9, Issue 7, Pages 773
出版商
MDPI AG
发表日期
2021-07-12
DOI
10.3390/vaccines9070773
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis
- (2021) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
- COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: implication for vaccination program?
- (2021) Stefano Gelibter et al. Multiple Sclerosis and Related Disorders
- Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis
- (2021) et al. Multiple Sclerosis Journal
- Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide
- (2021) Mehmet Fatih Yetkin et al. NEUROLOGICAL SCIENCES
- Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives
- (2021) Vikram Bhise et al. Neurotherapeutics
- Covid-19: First doses of vaccines in Scotland led to a substantial fall in hospital admissions
- (2021) Ingrid Torjesen BMJ-British Medical Journal
- COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review
- (2021) Fioravante Capone et al. Multiple Sclerosis and Related Disorders
- Willingness to be vaccinated against COVID-19: an exploratory online survey in a Portuguese cohort of multiple sclerosis patients
- (2021) Filipa Serrazina et al. Multiple Sclerosis and Related Disorders
- COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America
- (2021) Ricardo Alonso et al. Multiple Sclerosis and Related Disorders
- COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
- (2021) Sridhar Chilimuri et al. Vaccines
- COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
- (2021) Anthony T. Reder et al. CNS DRUGS
- COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021
- (2021) Anat Achiron et al. Multiple Sclerosis Journal
- Interferon system deficiencies exacerbating severe pandemic virus infections
- (2021) Silke Stertz et al. TRENDS IN MICROBIOLOGY
- Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
- (2021) Amber Salter et al. JAMA Neurology
- Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab
- (2021) Ramon E Flores-Gonzalez et al. Multiple Sclerosis and Related Disorders
- Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States
- (2021) Dawn M. Ehde et al. Multiple Sclerosis and Related Disorders
- Multiple sclerosis, rituximab, and COVID‐19
- (2021) Annette Langer‐Gould et al. Annals of Clinical and Translational Neurology
- COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
- (2021) Dominic Jack et al. Multiple Sclerosis and Related Disorders
- Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis
- (2021) Gauruv Bose et al. Multiple Sclerosis and Related Disorders
- COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
- (2021) Fabio Buttari et al. Multiple Sclerosis and Related Disorders
- Alemtuzumab in Covid era
- (2021) Aniello Iovino et al. Multiple Sclerosis and Related Disorders
- SARS‐CoV ‐2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad
- (2020) Sandra Amor et al. ANNALS OF NEUROLOGY
- Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System
- (2020) Mahmoud Gheblawi et al. CIRCULATION RESEARCH
- Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection
- (2020) Marco Chiarini et al. JOURNAL OF NEUROIMMUNOLOGY
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression
- (2020) Tiziana Carandini et al. Multiple Sclerosis Journal
- Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover
- (2020) Annarosa Soresina et al. PEDIATRIC ALLERGY AND IMMUNOLOGY
- The COVID-19 pandemic and the use of MS disease-modifying therapies
- (2020) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- COVID-19 and MS disease-modifying therapies
- (2020) Joseph R. Berger et al. Neurology-Neuroimmunology & Neuroinflammation
- COVID-19 in MS
- (2020) James D. Bowen et al. Neurology-Neuroimmunology & Neuroinflammation
- COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
- (2020) Mahdi Barzegar et al. Neurology-Neuroimmunology & Neuroinflammation
- COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
- (2020) D. Baker et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Cytokine storm and leukocyte changes in mild versus severe SARS‐CoV‐2 infection: Review of 3939 COVID‐19 patients in China and emerging pathogenesis and therapy concepts
- (2020) Jin Wang et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Clinical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal
- (2020) Victor Gomez‐Mayordomo et al. JOURNAL OF MEDICAL VIROLOGY
- COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
- (2020) Vittorio Mantero et al. JOURNAL OF NEUROLOGY
- Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse
- (2020) Nora Möhn et al. JOURNAL OF NEUROLOGY
- Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients
- (2020) Marcel S. Woo et al. JOURNAL OF NEUROLOGY
- COVID-19 in teriflunomide-treated patients with multiple sclerosis
- (2020) Amir Hadi Maghzi et al. JOURNAL OF NEUROLOGY
- Riesgo de infección por SARS-CoV-2 y resultados clínicos en pacientes con esclerosis múltiple en la Rioja (España)
- (2020) Federico Castillo Álvarez et al. MEDICINA CLINICA
- COVID-19 in multiple sclerosis: The Dutch experience
- (2020) Floor C Loonstra et al. Multiple Sclerosis Journal
- COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment
- (2020) Rick Dersch et al. Multiple Sclerosis Journal
- Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient
- (2020) Hannah Wurm et al. Multiple Sclerosis Journal
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
- (2020) Kizzmekia S. Corbett et al. NATURE
- Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
- (2020) Catharina Korsukewitz et al. Nature Reviews Neurology
- Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis
- (2020) Jens Devogelaere et al. NEUROLOGICAL SCIENCES
- Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study
- (2020) Gloria Dalla Costa et al. NEUROLOGICAL SCIENCES
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study
- (2020) Amit Bar-Or et al. NEUROLOGY
- Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis
- (2020) Céline Louapre et al. JAMA Neurology
- A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19
- (2020) Cristina Valencia-Sanchez et al. Multiple Sclerosis and Related Disorders
- Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
- (2020) Kulachanya Suwanwongse et al. Multiple Sclerosis and Related Disorders
- Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
- (2020) Emin Gemcioglu et al. Multiple Sclerosis and Related Disorders
- COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach
- (2020) Giovanna Borriello et al. Multiple Sclerosis and Related Disorders
- Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
- (2020) Christian Foerch et al. Multiple Sclerosis and Related Disorders
- COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile
- (2020) Ethel Ciampi et al. Multiple Sclerosis and Related Disorders
- B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran
- (2020) Farinaz Safavi et al. Multiple Sclerosis and Related Disorders
- Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic
- (2020) Mahsa Ghajarzadeh et al. Multiple Sclerosis and Related Disorders
- Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain
- (2020) Paloma Montero-Escribano et al. Multiple Sclerosis and Related Disorders
- COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
- (2020) Richard Hughes et al. Multiple Sclerosis and Related Disorders
- COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
- (2020) Giovanni Novi et al. Multiple Sclerosis and Related Disorders
- COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: insight to the immune response after COVID
- (2020) Celsi Fiorella et al. Multiple Sclerosis and Related Disorders
- COVID-19 outcomes in MS
- (2020) Erica Parrotta et al. Neurology-Neuroimmunology & Neuroinflammation
- The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
- (2020) Maria Rosa Ciardi et al. JOURNAL OF NEUROIMMUNOLOGY
- Mild COVID‐19 infection in a group of teriflunomide‐treated patients with multiple sclerosis
- (2020) Vittorio Mantero et al. JOURNAL OF NEUROLOGY
- Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register
- (2020) Nikos Evangelou et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
- (2020) Luca Bollo et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Genomic evidence for reinfection with SARS-CoV-2: a case study
- (2020) Richard L Tillett et al. LANCET INFECTIOUS DISEASES
- Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity
- (2020) Mingfeng Han et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY
- Vaccinations in patients with multiple sclerosis: A Delphi consensus statement
- (2020) Agostino Riva et al. Multiple Sclerosis Journal
- Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy
- (2020) Francesco Crescenzo et al. Multiple Sclerosis and Related Disorders
- Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab
- (2020) Jorge Matías-Guiu et al. Multiple Sclerosis and Related Disorders
- COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
- (2020) Virginia Meca-Lallana et al. Multiple Sclerosis and Related Disorders
- Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab
- (2020) Carlos Guevara et al. Multiple Sclerosis and Related Disorders
- Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia
- (2020) William L Conte Multiple Sclerosis and Related Disorders
- Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
- (2020) Matteo Lucchini et al. Multiple Sclerosis and Related Disorders
- Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
- (2020) Jeanine Rempe Thornton et al. Multiple Sclerosis and Related Disorders
- Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
- (2020) Clara Aguirre et al. Multiple Sclerosis and Related Disorders
- Characteristics of COVID-19 disease in multiple sclerosis patients
- (2020) Mahdi Barzegar et al. Multiple Sclerosis and Related Disorders
- MSCOVID19: Using social media to achieve rapid dissemination of health information
- (2020) Cassie Nesbitt et al. Multiple Sclerosis and Related Disorders
- Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod
- (2020) Giulia Mallucci et al. Multiple Sclerosis and Related Disorders
- COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
- (2020) Eva Fernández-Díaz et al. Multiple Sclerosis and Related Disorders
- Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
- (2020) Marco Iannetta et al. Multiple Sclerosis and Related Disorders
- Effects of MS disease-modifying therapies on responses to vaccinations: A review.
- (2020) John Robert Ciotti et al. Multiple Sclerosis and Related Disorders
- Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
- (2020) Marcello De Angelis et al. Multiple Sclerosis and Related Disorders
- COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response
- (2020) Ana Zabalza et al. EUROPEAN JOURNAL OF NEUROLOGY
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments
- (2020) Alice Laroni et al. Multiple Sclerosis Journal
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 in ocrelizumab-treated people with multiple sclerosis
- (2020) Richard Hughes et al. Multiple Sclerosis and Related Disorders
- Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway
- (2019) Sara Ghaderi et al. EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy
- (2018) H. K. Olberg et al. EUROPEAN JOURNAL OF NEUROLOGY
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
- (2011) S Cook et al. Multiple Sclerosis Journal
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now